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ABSTRACT
X-ray computed tomography (CT) requires an optimal compromise between image quality and patient
dose. While high image quality is an important requirement in CT, the radiation dose must be kept
minimal to protect the patients from ionizing radiation-associated risks. The use of probes based on
gold nanoparticles (AuNPs) along with active targeting ligands for specific recognition of cancer cells
may be one of the balanced solutions. Herein, we report the effect of folic acid (FA)-modified AuNP
as a targeted nanoprobe on the contrast enhancement of CT images as well as its potential for
patient dose reduction. For this purpose, nasopharyngeal KB cancer cells overexpressing FA receptors
were incubated with AuNPs with and without FA modification and imaged in a CT scanner with the
following X-ray tube parameters: peak tube voltage of 130KVp, and tube current–time products of 60,
90, 120, 160 and 250mAs. Moreover, in order to estimate the radiation dose to which the patient was
exposed during a head CT protocol, the CT dose index (CTDI) value was measured by an X-ray elec-
trometer by changing the tube current–time product. Raising the tube current–time product from 60
to 250mAs significantly increased the absorbed dose from 18mGy to 75mGy. This increase was not
associated with a significant enhancement of the image quality of the KB cells. However, an obvious
increase in image brightness and CT signal intensity (quantified by Hounsfield units [HU]) were
observed in cells exposed to nanoparticles without any increase in the mAs product or radiation
dose. Under the same Au concentration, KB cells exposed to FA-modified AuNPs had significantly
higher HU and brighter CT images than those of the cells exposed to AuNPs without FA modification.
In conclusion, FA-modified AuNP can be considered as a targeted CT nanoprobe with the potential
for dose reduction by keeping the required mAs product as low as possible while enhancing image
contrast.
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Introduction
Molecular imaging (MI) provides the means for visual represen-
tation, characterization and quantification of biological proc-
esses and has recently attracted a great deal of attention for
expanding the ability of medical imaging, particularly in the
field of cancer diagnosis. Among many different MI technolo-
gies, X-ray computed tomography (CT) is the most commonly
utilized diagnostic tool in clinics and it offers great advantages
over other imaging techniques such as superior spatial and
density resolution, ease of availability and cost-effectiveness.
However, some serious limitations encountered by CT imaging
in terms of sensitivity, specificity, spatial and temporal reso-
lution and patient dose issues need to be addressed. Utilizing
suitable contrast-enhancement agents with high X-ray absorp-
tion capability is a possible pathway to improve the effective-
ness of CT imaging. The use of iodine-based compounds as
the most commonly used CT contrast agents suffers the draw-
backs of short blood circulation lifetime, renal toxicity and
non-selectivity in tumour targeting, which hampers their
clinical use [1–5].
Recent attempts in the area of molecular imaging advo-
cate the implementation of nanotechnology to increase the
efficiency of cancer diagnosis. The use of nanoprobes as
potential contrast-enhancement agents in combination with
various molecular imaging technologies can offer great prom-
ises to break the detection limits of cancer diagnosis [6–8]. In
comparison to iodine-based compounds, gold nanoparticles
(AuNPs) are preferred as their higher atomic number and
electron density possess a stronger X-ray absorption coeffi-
cient, endowing them with the main prerequisites to be
employed as potential CT contrast agents [9]. This attribute,
along with their bio-inert and non-toxic properties, facile
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preparation, fabrication tunability and easy surface functional-
ization render the AuNPs as ideal candidates for CT contrast
agents with superior performance over iodine-based com-
pounds [10,11]. Moreover, through passive targeting, AuNPs
can diffuse rapidly via the disorganized and leaky vascula-
tures of the tumour and efficiently permeate throughout the
tumour matrix, a process known as the enhanced permeation
and retention (EPR) effect. The surface functionalization of
AuNPs with proper ligands that are identified by cancer cell
surface receptors can also provide an active targeting strat-
egy, leading to the enhanced uptake and internalization of
nanoparticles through receptor-mediated endocytosis (RME).
Taken together, AuNPs with preferential accumulation within
the tumour could provide efficient and targeted CT imaging,
thereby enhancing the specificity and sensitivity of imaging
[1,12,13].
The vitamin folic acid (FA) is a necessary ingredient for cell
proliferation. Cancer cells due to their rapid division rate
generally indicate a higher level of FA surface receptor
expression than normal cells [14,15]. Thus, the FA modifica-
tion of AuNPs endows them with a unique capability to par-
ticularly target cancer cells [16–19]. Specific recognition of
cancer cells provided by FA targeting, and then, enhanced
uptake and internalization of AuNPs in association with the
high X-ray absorption property of AuNPs may constitute a
targeted molecular CT imaging strategy [20,21].
A tremendous increase in the clinical usage of CT in the
past decade is associated with the increased individual and
population doses, and it raises concerns regarding the risks
of using ionizing radiation [22]. Currently, the radiation dose
in a CT scan contributes up to 70% of the total dose received
by patients undergoing different X-ray imaging examinations
[23]. Consequently, extensive efforts are being made to find a
competent strategy for dose reduction in CT examinations
while maintaining acceptable image quality. This is to ensure
that the ALARA principle established by the International
Commission on Radiological Protection (ICRP) is followed
which states that the radiation dose should be kept to As
Low As Reasonably Achievable [24].
We herein aim to investigate the effect of FA-modified
AuNPs on optimizing CT imaging in terms of image quality
and patient dose. For this purpose, nasopharyngeal KB cancer
cells overexpressing FA receptors treated with FA-AuNPs
were imaged and the CT signal intensity quantified by
Hounsfield units (HU) was measured. Moreover, the CT dose
index (CTDI) value as a measure of the radiation dose was
obtained in a CT head phantom by elevating the tube current
time product (mAs) as a general approach for improving the
image quality. Finally, the effects of elevating the mAs prod-
uct and existence of FA-AuNPs on improving the image qual-
ity were studied to assess the possible function of FA-AuNPs
for dose reduction in the process of CT imaging.
Material and methods
Material
FA-AuNPs (NB-GNP-FA) were prepared in R&D department of
Nanobon Company (Tehran, Iran) and a brief description of
the synthesis will be presented in the next section. Fetal
bovin serum (FBS) was purchased from BioSera Ltd. (Ringmer,
United Kingdom). Dulbecco’s modification of Eagle’s medium
(DMEM) and MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenylte-
trazolium bromide) were purchased from GIBCO (Invitrogen,
Germany). Trypsin- ethylenediaminetetraacetic acid (EDTA),
dimethyl sulphoxide (DMSO), penicillin–streptomycin solution
and folic acid, all were purchased from Sigma–Aldrich Corp.
(St Louis, MO).
Synthesis of folic acid-conjugated gold nanoparticles
(FA-AuNPs)
FA-AuNPs were prepared according to the method recently
reported by Li et al and Neshastehriz et al [25,26]. Briefly, to
obtain 100ml of F-AuNPs, an aqueous solution of HAuCl4
(Au; 150 ppm) and trinatrium citrate (150mg) was heated to
80 C while vigorously stirred for about two hours until the
colour of the solution turned to deep red. After cooling the
solution to room temperature, a solution of FA (150mg in
5ml ethanol) was added and the resultant solution was soni-
cated for 10min. The formation of FA-AuNPs was confirmed
by spectrophotometer and Fourier transform infrared
spectroscopy (FTIR).
Characterization of nanoparticles
Particles size and morphology determination
The morphological characteristics of nanoparticles were ana-
lysed by a Zeiss LEO 906 transmission electron microscope
(TEM). For this purpose, nanoparticles were suspended in dis-
tilled water and sonicated for 10min. A small drop of suspen-
sion was deposited onto a carbon-coated copper grid and
allowed to be evaporated. Then, the perfectly dried grid was
observed under transmission electron microscope at 120 KV.
Furthermore, size distribution and effective hydrodynamic
size of nanoparticles were determined by dynamic laser light
scattering (DLS) using a Malvern Zetasizer, NANO ZS (Malvern
Instruments Limited, UK).
Surface charge
Zeta potential is an indicator of surface charge, which deter-
mines particle stability in dispersion. We determined zeta
potential of nanoparticles using a Malvern Zetasizer, NANO
ZS (Malvern Instruments Limited, UK).
UV-visible absorption studies
UV–visible (UV–vis) absorption spectroscopic measurements
were recorded on a single-beam UV–vis spectrometer, Agilent
8453, using quartz cells of 1 cm path length and DI water as
the reference at room temperature.
Fourier transform infrared spectroscopy (FTIR) studies
Fourier transform infrared (FTIR) spectra were recorded by
using a Shimadzu FT-IR 4300 instrument equipped with
pressed KBr pellets in the wavenumber range 500 to
3600 cm1 at room temperature.
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Cell culture
Our experiments were conducted on KB cell line, derived
from human mouth epidermal carcinoma. Cells were cultured
as a monolayer in DMEM cell growth media with L-glutamine
and NaHCO3 supplemented with 10% FBS, 100 units/ml peni-
cillin and 100 lg/ml streptomycin and incubated in a humidi-
fied atmosphere containing 5% CO2 and 95% air at 37 C.
Cytotoxicity effects of nanoparticles
To determine the cytotoxicity of AuNPs and FA-AuNPs
towards KB cells, an MTT assay was performed. The MTT
assay is a colorimetric method based on the reduction of the
ratio of yellow tetrazolium dye salt to insoluble purple forma-
zan that indicates the cytotoxicity level of a chemical. First,
KB cells were seeded in 96-well cell culture plate at a density
of 1 104 cells per well and incubated for 24 h at 37 C in a
5% CO2-saturated humidified atmosphere. The serial concen-
trations of AuNPs and FA-AuNPs (0–100mg/ml in medium
solution) were then prepared and added into each well. After
12-h incubation, 20 ll of MTT reagent was added to each
well and the cells were further incubated for 4 h. Then, the
MTT-containing medium was removed and replaced with for-
mazan crystals dissolved in 10 ll of DMSO and the plates
were kept in the dark at room temperature for 15min.
Finally, the plates were read immediately in a microplate
reader (DYNEX MRX, USA) at a 570 nm wavelength and,
thereby, the cell viability percentage was calculated.
CT imaging of cancer cells
KB cells were seeded in six-well cell culture plates at a dens-
ity of 1 106 cells per well and incubated for 24 h at 37 C in
a humidified 5% CO2 atmosphere. The serial concentrations
of AuNPs and FA-AuNPs in medium solution ranged from 0
to 90 mg/ml were prepared and added into each well. After
12-h incubation, cells were washed three times with PBS to
remove unloaded nanoparticles. Cells were then trypsinized,
centrifuged and resuspended with 100 mL PBS and placed in
1.5-ml Eppendorf tubes. The remaining capacity of the tubes
were filled with agar gel. Next, Eppendorf tubes containing
cell suspensions were embedded in a self-designed scanning
holder made of plexiglas and then scanned using a CT imag-
ing system (Somatom Balance, Siemens Medical Sotions) with
the following operation parameters:
Peak kilovoltage of 130 KVp; tube current–time products
of 60, 90, 120, 160 and 250 mAs; Slice thickness of 1mm and
field of view of 199mm100mm.
The acquired CT images of the Eppendorf tubes were ana-
lysed by using RadiAnt DICOM Viewer 2.2.9 (32 bit) software
(Medixant Company, Poland).
Dose measurement
CTDI value is the most common parameter for estimating
radiation dose from a CT examination, developed by Shop
et al. [27]. In order to estimate the radiation dose by chang-
ing the tube current–time product in a head CT protocol,
CTDI value was measured with ion chamber. To this end, a
CT ion chamber (RTI Electronics, M€olndal, Sweden) was
placed in the centre hole of a CT head phantom (16 cm in
diameter and 15 cm in length) and connected to a chamber
adaptor and chamber adaptor connected to black piranha
(Piranha, RTI Electronics). The phantom was aligned to the
centre of the gantry using positioning lasers. Axial scanning
of the phantom was performed in all five embedded holes
one by one, centre, 12 o’clock, 3 o’clock, 6 o’clock and then
9 o’clock positions under different tube current–time prod-
ucts, ranging from 60–250mAs and fixed peak tube voltage
of 130 KVp. Dosimetry information was stored on a Tablet
running Ocean software (RTI Electronics).
Statistical analysis
Statistical analysis was performed by using SPSS software
(version11). One-way analysis of variance (ANOVA) statistical
method was used to evaluate the significance of the experi-
mental data. A value of p< .05 was considered statistically
significant.
Results
Characterization of the nanoparticles
TEM was performed to assess the morphological characteris-
tics of FA-AuNPs. Figure 1 shows a typical TEM micrograph of
the synthesized FA-AuNPs. The results suggest that the nano-
particles are well dispersed and appear to be spherical in
shape with a size distribution of 10–30 nm. The hydrodynamic
size and zeta potential of nanoparticles were measured using
DLS and zeta potential analyzer, respectively. Obtained results
are shown in Figure 2(a). It was determined that hydro-
dynamic size of nanoparticles is 33.8 nm. Moreover, zeta
potential of the synthesized FA-AuNPs was 12.5mV, as
shown in Figure 2(b). Figure 3 shows the UV-visible absorp-
tion spectrum of FA-AuNPs. Accordingly, it may be found FA-
AuNPs has three absorption peaks in the range of UV-visible
Figure 1. TEM image of the synthesized FA-AuNPs, suggesting that the nano-
particles are well dispersed and appear to be spherical in shape with a size dis-
tribution of 10–30 nm.
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wavelengths. By looking at the UV-Vis absorption spectrum of
FA-AuNPs, we identified that FA-AuNPs absorption peaks are
about 280 nm and 360 nm pertaining to folate conjugation
and about 530 nm pertaining to AuNPs. Figure 4(a) shows
FTIR spectrum of folic acid in which wavenumbers of 3418
and 3544 cm1 correspond to stretching vibrations of amide
and amine groups. Characteristic bands of C¼O group are
about 1694 and 1607 cm1. FTIR spectrum of AuNPs stabi-
lized by trisodium citrate is presented in Figure 4(b). In this
figure, the peaks at 2923, 1635 and 3442 cm1 correspond to
stretching vibration of CH, C¼O and OH groups, respectively.
A strong peak must be seen in Figure 4(b) in the range of
1690–1760 cm1 for stretching vibration of C¼O group while
this peak is absent. The reason of this phenomenon may be
pertained to some events occurred for carboxyl groups of cit-
rate and coverage of AuNPs with citrate is an option. Finally,
Figure 4(c) shows FTIR spectrum of FA-AuNPs in which peaks
at 1693, 1638 and 1607 cm1 correspond to the stretches of
Figure 2. (a) Size distribution of the synthesized FA-AuNPs (peak: 33.8 nm). (b) Zeta potential distribution of the synthesized FA-AuNPs (peak: 12.5mV).
Figure 3. UV–visible spectrum of AuNPs with and without conjugation with folic acid [Reprinted with permission from Elsevier].
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C¼O groups and the peak at 3422 cm1 correspond to OH
group. With comparing Figure 4(a) and (c), it may be inferred
the absence of amine group peaks in Figure 4(c) is due to
conjugation of amine groups of folic acid to AuNPs and this
document shows that folic acid has been conjugated to
AuNPs.
Cytotoxicity assay
We investigated the cytotoxicity effects of the nanoparticles
towards KB cells using an MTT colorimetric assay. Figure 5
shows the cell viability results for KB cells after 12-h incuba-
tion with AuNPs and FA-AuNPs at various concentrations
ranging from 0 to 100 lg/ml. According to this figure, AuNPs
do not exhibit apparent cytotoxicity even at the highest con-
centration of 100 lg/ml. The viability of the cells treated with
AuNPs and FA-AuNPs at 100 lg/ml Au concentration were
94% and 83%, respectively, demonstrating an appropriate
cytocompatibility level for the nanoparticles used in the
present study.
CT imaging of cancer cells
To explore the effect of the FA targeting of AuNPs on a CT
contrast, KB cells were exposed to both targeted- and non-
targeted nanoparticles with different Au concentrations
(0, 20, 30, 45 and 90 mg/ml) and were imaged using a CT
imaging system. The results of quantitative analysis of CT val-
ues at different tube current–time products (60, 90, 120, 160
and 250mAs) are presented in Figures 6–10. From the CT
Figure 4. FTIR spectra of folic acid, AuNPs stabilized with trisodium citrate and FA-AuNPs [Reprinted with permission from Elsevier].
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Figure 5. The viability of KB cells after 12-h incubation with AuNPs and FA-
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uct of 60 mAs).
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images of the tubes, it was obvious that the cells not
exposed to nanoparticles were not detectable even at the
highest mAs. However, the presence of nanoparticles
increased the brightness of the CT images and the cells
appeared as bright spots at the bottom of the Eppendorf
tubes. Meanwhile, the brightness of the CT images increases
with the increase of Au concentration. Since it is difficult to
visually differentiate the brightness of the CT images, a quan-
titative analysis of the CT signal intensity as a function of Au
concentration was performed. The quantitative analysis of the
CT values further demonstrates the CT contrast-enhancement
performance of the AuNPs. Accordingly, the CT values of KB
cells treated with AuNPs (with or without FA modification)
enhanced dramatically in comparison to the cells not
exposed to nanoparticles. Moreover, the observed CT value
enhancement in the presence of nanoparticles was strongly
dependent on Au concentration, where a higher Au concen-
tration caused the higher CT value enhancement.
Importantly, under the given Au concentration, the cells
exposed to FA-AuNPs exhibit significantly higher CT contrast
enhancement than those of the cells exposed to non-tar-
geted AuNPs. The CT value of the cells not exposed to nano-
particles was only 2.5 HU, whereas the cells treated with
AuNPs and FA-AuNPs (Au concentration: 90 mg/ml) reached
the higher CT values of 608 and 683 HU, respectively (at
130 KVp and 250mAs). The minimum detectable concentra-
tion of non-targeted AuNPs in order to create a visible
contrast in the CT images was 45 mg/ml. However,
FA-AuNPs at the lower concentration of 20 mg/ml created
enough increase in image brightness that could be distin-
guished by the human eye.
Dose measurement
Figure 11 displays the dosimetry results of CT scanning of the
head phantom at different mAs products and a fixed peak
tube voltage of 130 KVp. As shown in this figure, elevating
the mAs product significantly increases the values of the
CTDI. Accordingly, elevating the tube current–time product
from 60 to 250 mAs significantly increased the absorbed
dose from 18 mGy to 75 mGy during a head CT protocol.
Discussion
In the present study, we have synthesized FA-modified
AuNPs and assessed their potential to be used as the nanop-
robes in the targeted CT imaging of cancer cells. We selected
AuNPs with a diameter ranged from 10 to 30 nm (as observed
in Figure 1) according to the recent report of the intensive
X-ray absorption of AuNPs at this range [28,29]. Dou et al.
investigated the size-dependent contrast enhancement effect
of AuNPs for CT imaging and found that within the size
range of 3–50 nm, AuNPs sized around 15 nm show a superior
CT contrast performance. Likewise, 15 nm AuNPs exhibited
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Figure 8. The CT values of KB cells treated with AuNPs and FA-AuNPs (12 h) at
different concentrations (tube voltage of 130 kVp and tube current–time
product of 120mAs).
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Figure 9. The CT values of KB cells treated with AuNPs and FA-AuNPs (12 h) at
different concentrations (tube voltage of 130 kVp and tube current–time
product of 160mAs).
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the greatest radiosensitizing effect for the enhancement of
radiotherapy. Therefore, the selected AuNPs in the present
study have the optimized size to be utilized as X-ray
theranostic agents for the simultaneous enhancement of CT
imaging and radiotherapy.
Understanding the physical rationale behind the interaction
of X-ray with material can be helpful for developing suitable CT
contrast agents. The photoelectric effect is the predominant
mechanism of the interaction of X-ray with material at the kV
energy level of clinical CT imaging, which is responsible for X-
ray attenuation. The photoelectric absorption cross-section is
strongly dependent on the atomic number (Z) of interacting
material, which is proportional to Z4. As a consequence, high-Z
materials represent a higher probability of emitting secondary
radiations (e.g. Auger electrons and photoelectrons), causing
an increased X-ray absorption. Accordingly, AuNPs, owing to
their high atomic number (Z¼ 79) and electron density, have
an intense X-ray attenuation coefficient, which renders them as
elegant CT contrast agents [30,31].
Several reports have demonstrated the superior CT con-
trast performance of AuNPs compared to the routinely used
CT contrast agents in clinic. Kim et al. demonstrated a 5.7-
fold higher X-ray attenuation coefficient for polyethylene gly-
col (PEG)-coated AuNPs than a conventional iodine-based CT
contrast agent (Ultravist). Indeed, 33mg/ml of the PEG-AuNPs
and 407.6mg/ml of Ultravist (containing 189mg iodine)
resulted in an equivalent enhancement in the CT values [32].
In another study, Peng et al. compared the CT contrast
enhancement of AuNPs and Omnipaque, another conven-
tional iodine-based CT contrast agent. Under the same
concentration of 0.1M, the X-ray attenuation of dendrimer-
entrapped gold nanoparticles (Au DENPs) was found to be
30% higher than that of Omnipaque [20].
The decoration of AuNPs with FA targeting moiety can fur-
ther enhance the therapeutic and diagnostic applications of
AuNPs [33–35]. This is accomplished by the specific recogni-
tion of the FA receptors by FA conjugated NPs on cancer cell
membranes, which accelerates the cellular internalization of
AuNPs via RME, thus enhancing the intracellular content of
AuNPs. Zhou et al. reported a targeted chemotherapy strat-
egy for the efficient delivery of gold nanoclusters (AuNCs)
carrying cisplatin prodrug and demonstrated an accelerated
cellular internalization and enhanced tumour accumulation
accompanied by the retention of the nanocarriers due to FA
modification [36]. Remarkable successes in improving radio-
therapy effectiveness have also been provided by utilizing
FA-modified AuNPs [37]. Furthermore, in our previous works,
we have demonstrated the positive impact of FA targeting
on the increase in the photothermal therapy efficiency of
AuNPs [38,39].
In the area of cancer diagnosis, the use of FA targeting has
recently yielded a remarkable breakthrough. For example, in
the recent report by Hu et al., multifunctional FA-targeted
Fe3O4 @Au core/shell nanostars were developed for targeted
magnetic resonance (MR) and CT imaging [40]. Inductively
coupled plasma-optical emission spectroscopy (ICP-OES) and
TEM imaging were used to evaluate the targeting potential of
the nanostars towards HeLa cells with high and low levels of
FA receptors, known as HeLa-HFAR and HeLa-LFAR, respect-
ively. Under the same Au concentration, the intracellular con-
tent of the nanostars in HeLa-HFAR cells was significantly
higher than that in HeLa-LFAR cells. Due to existence of
the magnetic core, the treatment of HeLa cancer cells with the
nanostars decreased the MR signal intensity and the
T2-weighted MR images became darker. However, the decrease
in MR signal intensity for the HeLa-HFAR cells was more prom-
inent than for the HeLa-LFAR cells. On the other hand, the CT
images of the HeLa-HFAR cells demonstrated an increased
brightness and superior CT contrast enhancement rather than
the HeLa-LFAR cells, which are attributed to the greater cellular
uptake of FA-modified nanostars in cancer cells overexpressing
FA receptors. These findings agree with the results of the pre-
sent study, where under the same Au concentration, KB cells
treated with FA-AuNPs revealed significantly higher CT contrast
enhancement than the cells treated with AuNPs. Table 1 repre-
sents the role of FA targeting on optimizing the CT contrast
performance of AuNPs in terms of “DHUFA-AuNPs – DHUAuNPs”.
Here, DHUFA-AuNPs and DHUAuNPs refer to the increase in the CT
value of the KB cells due to treatment with FA-AuNPs and
AuNPs at the same Au concentrations relative to the CT value
of the control group, respectively.
CT imaging requires an optimal compromise between
image quality and patient dose. It is a key consideration to
work with a minimal dose to follow the ALARA principle
whereby the patient would be protected from the risks asso-
ciated with ionizing radiation. A general reduction in the
tube current as a possible means for dose reduction is always
associated with impairment in the image quality due to
increased pixel noise [24]. As shown in Figure 11, under the
tube voltage of 130 KVp, elevating the mAs product
significantly increases the absorbed dose during a head CT
protocol. This increase however is not associated with an
Table 1. The resultant increase in the CT value of KB cells caused by the FA
modification of AuNPs (DHU FA-AuNPs – DHU AuNPs). DHU FA-AuNPs and DHU AuNPs
stand for the increase in the CT value of KB cells due to treatment with FA-
AuNPs and AuNPs at the same Au concentration relative to the CT value of
the control group, respectively.
Au concentration
mAs product 20 mg/ml 30 mg/ml 45 mg/ml 90 mg/ml
60 92 112 104 82
90 91 109 80 115
120 74 73 74 71
160 92 120 65 67
250 85 115 80 750
10
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60 90 120 160 250
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 (m
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)
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Figure 11. The CTDI values measured from the CT scanning of a head phantom
at different mAs products and fixed peak tube voltage of 130 kVp.
ARTIFICIAL CELLS, NANOMEDICINE, AND BIOTECHNOLOGY 1999
appreciable enhancement of image quality. Table 2 quantita-
tively compares the respective CT value enhancement of KB
cells caused by the (1) elevating mAs product, (2) treatment
with AuNPs and (3) treatment with FA-AuNPs. Accordingly,
elevating the tube current–time product from 60 to 250 mAs
led to a 4.17-fold increase in radiation dose, whereas the
corresponding CT value enhancement was not noticeable
(DHU¼ 41). In sharp contrast, the existence of AuNPs with
and without FA modification dramatically enhanced the CT
value without any increase in the radiation dose by keeping
the mAs product at the minimum level. Indeed, the resultant
increase in the CT value of the cells exposed to nanoparticles
was much more than that obtained by elevating the mAs
product. Therefore, AuNPs present the potential for dose
reduction in CT examinations by lowering the minimal mAs
product required, while enhancing the contrast of CT images.
The potential of AuNPs for contrast enhancement and dose
reduction in optimizing CT imaging can be considerably uti-
lized in combination with FA targeting.
Conclusions
Utilizing AuNPs with high X-ray absorption properties in com-
bination with FA targeting presents a CT-based molecular
nanoprobe and offers a targeted CT imaging strategy for spe-
cific recognition of cancer cells. Elevating the mAs product as
a general approach for enhancing image quality is associated
with increasing patient dose while the resultant increase in
image quality is not noticeable. The use of FA-modified
AuNPs represents a competent alternative to the approach of
elevating mAs product for improving image quality. Indeed,
FA-modified AuNPs provide a good potential for optimizing
CT imaging by keeping the required mAs product and the
radiation dose as low as possible while enhancing the image
contrast.
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